[Exclusive] New Drug Company Fermizi Technology Received A Few Million Dollars in Series Pre-A Financing

According to VCBeat, on June 14, 2019, a new drug company named Fermizi Technology in Guangzhou just completed a few million dollars in Series Pre-A financing. This round of financing was led by Challenjers Capital and Panda Capital.

Founded in 2018 by Dr. Daiguo Ddeng, Fermizi Technology focuses on the development of AI-assisted pharmaceutical technology for small molecule drugs and works with CRO and pharmaceutical companies to improve the efficiency of new drug development through AI technology. The goal of Fermizi Technology is to develop cheap drugs for patients.

According to data from VCBeat, new drug companies like Fermizi that use AI to develop new drugs are growing fast around the world. They have accumulated a total of $1.31 billion in the financing, of which 80% are in the round A and the previous stage.

Fermizi's team consists of experts in AI technical and drug development. After a few months, Fermizi Technology's AI pharmaceutical platform already gained three core technologies: molecular screening of molecular drugs, automatic generation of new molecular compound data, and optimization of lead small molecule compounds. These technologies were recognized by many drug research and development companies.

Challenjers Capital determined to invest in the start-ups, which create authentic products and services, instead of companies, which inflate their margins with marketing fees.

Founded in 2015, Panda Capital is a disciplined early-stage investor focused on companies from Angel to Series B stages and strive to become their first or the second institutional investor. They focus on fast-growing tech startups.